Daily Brief Health Care: Inner Mongolia Furui Medical Scie, Galera Therapeutics , Legend Biotech Corp, Windtree Therapeutics , Neurocrine Biosciences, Seres Therapeutics, Stevanato Group SpA and more

• The review period ends on 31 October, the changes should be announced on 29 November and will be effective after the close of trading on 13 December.
• We forecast 4 potential changes for the index in December where there could be buying of 0.5-3x ADV in the adds and selling of between 0.5-1.3x ADV in the deletes.
• The forecast adds have drifted lower versus the forecast deletes following the rally in the markets and the large ETF creations. That could reverse from now till review period end.

• Positive results from a Phase 3 clinical trial show that avasopasem reduces the severity of symptomatic oral mucositis (SOM) and decreases the need for opioid analgesics.
• Galera Therapeutics plans to submit a New Drug Application (NDA) to the FDA based on these promising results.
• There is potential for avasopasem to become a new standard of care for patients receiving radiation therapy for head and neck cancer.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• We do not want to make a premature conclusion about this acquisition too early. For both Legend Bio and Genscript, this acquisition is worth considering, given the geopolitical risks.
• There could be difference in expectations between buyers and sellers regarding the acquisition price. For fear of losing their jobs, Legend Bio’s management may not be happy about being acquired.
• Considering the high uncertainty, our suggestion is that investors spend more time on the fundamentals of Legend Bio, rather than just betting on the success of the acquisition.

• Zacks Small-Cap Research Note for Windtree Therapeutics (WINT)

• Neurocrine Biosciences, in its second quarter earnings call for 2024, highlighted significant achievements and strategic movements, setting a dynamic course for its future.
• As CEO Kevin Gorman prepares to step down, the company reported a robust year with strong financial and clinical developments, though faced challenges typical of a biotech firm scaling its operations and research endeavors.
• Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

• Seres Therapeutics, a leading microbiome therapeutics company, recently held its second-quarter 2024 earnings call.
• The company is refining its strategic direction, focusing on live biotherapeutics, while simultaneously divesting its VOWST business to Nestlé Health Science.
• This transaction, expected to close soon, involves the sale of the VOWST commercial rights for $155 million.

• Stevanato Group’s second quarter 2024 earnings results reflect a mixed performance characterized by robust revenue growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, offset by challenges in the Engineering segment.
• Challenges included project delays and higher costs primarily related to supply chain disruptions.
• Stevanato Group provided comprehensive updates on operational initiatives aimed at optimizing production and improving efficiency across their locations, especially in Denmark and Italy.